Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer
E Chirshev, KC Oberg, YJ Ioffe… - Clinical and translational …, 2019 - Springer
Abnormal regulation and expression of microRNAs (miRNAs) has been documented in
various diseases including cancer. The miRNA let-7 (MIRLET7) family controls …
various diseases including cancer. The miRNA let-7 (MIRLET7) family controls …
MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction
Breast cancer is a major health problem that affects one in eight women worldwide. As such,
detecting breast cancer at an early stage anticipates better disease outcome and prolonged …
detecting breast cancer at an early stage anticipates better disease outcome and prolonged …
The network of non-coding RNAs in cancer drug resistance
F Corrà, C Agnoletto, L Minotti, F Baldassari… - Frontiers in …, 2018 - frontiersin.org
Non-coding RNAs (ncRNAs) have been implicated in most cellular functions. The disruption
of their function through somatic mutations, genomic imprinting, transcriptional and post …
of their function through somatic mutations, genomic imprinting, transcriptional and post …
Epigenetics of aging and Alzheimer's disease: Implications for pharmacogenomics and drug response
R Cacabelos, C Torrellas - International journal of molecular sciences, 2015 - mdpi.com
Epigenetic variability (DNA methylation/demethylation, histone modifications, microRNA
regulation) is common in physiological and pathological conditions. Epigenetic alterations …
regulation) is common in physiological and pathological conditions. Epigenetic alterations …
Influence of microRNAs and long non-coding RNAs in cancer chemoresistance
D Ayers, J Vandesompele - Genes, 2017 - mdpi.com
Innate and acquired chemoresistance exhibited by most tumours exposed to conventional
chemotherapeutic agents account for the majority of relapse cases in cancer patients. Such …
chemotherapeutic agents account for the majority of relapse cases in cancer patients. Such …
Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer
J Wu, S Zhang, J Shan, Z Hu, X Liu, L Chen, X Ren… - Cancer letters, 2016 - Elsevier
High mobility group AT-hook 2 (HMGA2) is involved in a wide spectrum of biological
processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) …
processes and is upregulated in several tumors. Here, we collected 273 breast cancer (BC) …
miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis
Z Zhang, H Zhang, J Yu, L Xu, X Pang, Q Xiang… - Breast cancer research …, 2022 - Springer
Purpose Accumulating evidence has shown that microRNAs (miRNAs) are promising
biomarkers of neoadjuvant chemotherapy (NAC) response in breast cancer (BC). However …
biomarkers of neoadjuvant chemotherapy (NAC) response in breast cancer (BC). However …
Identification of specific miRNA signature in paired sera and tissue samples of Indian women with triple negative breast cancer
Of several subtypes of breast cancer, triple negative breast cancer (TNBC) is a highly
aggressive tumor that lacks expression of hormone receptors for estrogen, progesterone …
aggressive tumor that lacks expression of hormone receptors for estrogen, progesterone …
Clinical theragnostic relationship between drug-resistance specific miRNA expressions, chemotherapeutic resistance, and sensitivity in breast cancer: a systematic …
R Jayaraj, MR Madhav, SG Nayagam, A Kar… - Cells, 2019 - mdpi.com
Awareness of breast cancer has been increasing due to early detection, but the advanced
disease has limited treatment options. There has been growing evidence on the role of …
disease has limited treatment options. There has been growing evidence on the role of …
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
A Ritter, M Hirschfeld, K Berner… - International …, 2020 - spandidos-publications.com
Due to the positive association between neoadjuvant chemotherapy (NACT) and the
promising early response rates of patients with triple negative breast cancer (TNBC) …
promising early response rates of patients with triple negative breast cancer (TNBC) …